• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Mapping kinase-dependent tumor immune adaptation with multiplexed single-cell CRISPR screens.通过多重单细胞CRISPR筛选绘制激酶依赖性肿瘤免疫适应性图谱。
bioRxiv. 2026 Jan 9:2026.01.08.698516. doi: 10.64898/2026.01.08.698516.
2
Functional profiling of murine glioma models highlights targetable immune evasion phenotypes.功能分析揭示了靶向治疗的免疫逃避表型。
Acta Neuropathol. 2024 Nov 27;148(1):74. doi: 10.1007/s00401-024-02831-w.
3
A co-culture model to study modulators of tumor immune evasion through scalable arrayed CRISPR-interference screens.通过可扩展的阵列 CRISPR 干扰筛选来研究肿瘤免疫逃逸调节剂的共培养模型。
Front Immunol. 2024 Oct 21;15:1444886. doi: 10.3389/fimmu.2024.1444886. eCollection 2024.
4
Developing an Arrayed CRISPR-Cas9 Co-Culture Screen for Immuno-Oncology Target ID.开发用于免疫肿瘤学靶标鉴定的阵列 CRISPR-Cas9 共培养筛选。
SLAS Discov. 2020 Jul;25(6):581-590. doi: 10.1177/2472555220916457. Epub 2020 May 6.
5
Identification of genetic modifiers enhancing B7-H3-targeting CAR T cell therapy against glioblastoma through large-scale CRISPRi screening.通过大规模 CRISPRi 筛选鉴定增强 B7-H3 靶向 CAR T 细胞治疗胶质母细胞瘤的遗传修饰物。
J Exp Clin Cancer Res. 2024 Apr 1;43(1):95. doi: 10.1186/s13046-024-03027-6.
6
Checkpoint kinase 1/2 inhibition potentiates anti-tumoral immune response and sensitizes gliomas to immune checkpoint blockade.抑制检查点激酶 1/2 增强了抗肿瘤免疫反应,并使神经胶质瘤对免疫检查点阻断敏感。
Nat Commun. 2023 Mar 22;14(1):1566. doi: 10.1038/s41467-023-36878-2.
7
TRIM28 drives immune evasion via PARP1 SUMOylation and NAD depletion in clear cell renal cell carcinoma.TRIM28通过聚(ADP-核糖)聚合酶1(PARP1)的SUMO化修饰和NAD消耗在透明细胞肾细胞癌中驱动免疫逃逸。
J Immunother Cancer. 2025 Oct 23;13(10):e013025. doi: 10.1136/jitc-2025-013025.
8
Multimodal pooled Perturb-CITE-seq screens in patient models define mechanisms of cancer immune evasion.多模态联合 Perturb-CITE-seq 筛选在患者模型中定义了癌症免疫逃逸的机制。
Nat Genet. 2021 Mar;53(3):332-341. doi: 10.1038/s41588-021-00779-1. Epub 2021 Mar 1.
9
IL-4 mediated TAP2 downregulation is a dominant and reversible mechanism of immune evasion and immunotherapy resistance in non-small cell lung cancer.白细胞介素-4介导的TAP2下调是非小细胞肺癌免疫逃逸和免疫治疗耐药的主要且可逆机制。
Mol Cancer. 2025 Mar 17;24(1):80. doi: 10.1186/s12943-025-02276-z.
10
CIS deletion by CRISPR/Cas9 enhances human primary natural killer cell functions against allogeneic glioblastoma.CRISPR/Cas9 介导的 CIS 缺失增强了人源原代自然杀伤细胞对同种异体胶质母细胞瘤的杀伤功能。
J Exp Clin Cancer Res. 2023 Aug 10;42(1):205. doi: 10.1186/s13046-023-02770-6.

本文引用的文献

1
Microgravity-cultured glioblastoma organoids integrated with microfluidic chip for CAR-γδ T evaluation.
Commun Biol. 2025 Dec 18;8(1):1791. doi: 10.1038/s42003-025-09390-0.
2
Immunotherapeutic strategies targeting the PVR-TIGIT/CD96/CD226 signaling pathway in glioma treatment.
Ann Med. 2025 Dec;57(1):2588717. doi: 10.1080/07853890.2025.2588717. Epub 2025 Nov 18.
3
Hypoxia-induced MT2A-tetrameric PKM2 interaction maintains PKM2 activity in a copper-ion-dependent manner.
Cell Insight. 2025 Sep 24;4(6):100277. doi: 10.1016/j.cellin.2025.100277. eCollection 2025 Dec.
4
CAR-T cells immunotherapy in the treatment of glioblastoma.嵌合抗原受体T细胞免疫疗法治疗胶质母细胞瘤
Cancer Immunol Immunother. 2025 Nov 6;74(12):363. doi: 10.1007/s00262-025-04222-w.
5
Spatiotemporal gene expression and cellular dynamics of the developing human heart.发育中的人类心脏的时空基因表达与细胞动力学
Nat Genet. 2025 Nov;57(11):2756-2771. doi: 10.1038/s41588-025-02352-6. Epub 2025 Oct 29.
6
The tumor immune microenvironment: implications for cancer immunotherapy, treatment strategies, and monitoring approaches.肿瘤免疫微环境:对癌症免疫治疗、治疗策略及监测方法的影响
Front Immunol. 2025 Sep 22;16:1621812. doi: 10.3389/fimmu.2025.1621812. eCollection 2025.
7
Harnessing ferroptosis to transform glioblastoma therapy and surmount treatment resistance.利用铁死亡来改变胶质母细胞瘤的治疗并克服治疗抗性。
Cell Death Discov. 2025 Oct 7;11(1):448. doi: 10.1038/s41420-025-02744-x.
8
Inhibition of ICAM1 diminishes stemness and enhances antitumor immunity in glioblastoma via β-catenin/PD-L1 signaling.抑制细胞间黏附分子1(ICAM1)可通过β-连环蛋白/程序性死亡配体1(PD-L1)信号通路降低胶质母细胞瘤的干性并增强抗肿瘤免疫力。
Nat Commun. 2025 Sep 30;16(1):8642. doi: 10.1038/s41467-025-63796-2.
9
Identification of , and as Hub Genes of Therapeutic Resistance in Glioblastoma Multiforme Bioinformatics Analysis.鉴定 和 作为多形性胶质母细胞瘤治疗耐药的枢纽基因:生物信息学分析
Cancer Genomics Proteomics. 2025 Sep-Oct;22(5):791-808. doi: 10.21873/cgp.20537.
10
Immune evasion in cancer: mechanisms and cutting-edge therapeutic approaches.癌症中的免疫逃逸:机制与前沿治疗方法。
Signal Transduct Target Ther. 2025 Jul 31;10(1):227. doi: 10.1038/s41392-025-02280-1.

通过多重单细胞CRISPR筛选绘制激酶依赖性肿瘤免疫适应性图谱。

Mapping kinase-dependent tumor immune adaptation with multiplexed single-cell CRISPR screens.

作者信息

Shi Lingting, Giglio Ross M, Cai Qingyuan, Vaikunthan Mathini, Hong Justin, Naqvi Abdullah, Milea Marina, Khanshali Hannah, Schoonen Anna, Hou Nicholas, Guo Jonathan, Fraidenburg Melanie, Shen Xumin, Malinowski Seth W, Ligon Keith L, Rabadán Raúl, Azizi Elham, McFaline-Figueroa José L

机构信息

Irving Institute for Cancer Dynamics, Columbia University, New York, NY, 10027, USA.

Department of Biomedical Engineering, Columbia University, New York, NY, 10027, USA.

出版信息

bioRxiv. 2026 Jan 9:2026.01.08.698516. doi: 10.64898/2026.01.08.698516.

DOI:10.64898/2026.01.08.698516
PMID:41542636
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12803220/
Abstract

Immune dysfunction in cancer is enacted by multiple programs, including tumor cell-intrinsic responses to distinct immune subpopulations. A subset of these immune evasion programs can be systematically recapitulated through direct tumor-immune interactions . Here, we present an integrated, high-throughput single-cell CRISPR screening framework focused on the protein kinome for mapping the tumor-intrinsic regulation of T cell-driven immune pressure in glioblastoma (GBM). We combine pooled CRISPR interference and activation (CRISPRi/a) with immune-matched NY-ESO-1 antigen-specific allogeneic GBM-T cell co-culture and massively multiplexed single-cell transcriptomics to systematically quantify how genetic perturbation reshapes baseline tumor state and adaptive responses across graded effector-to-target ratios. We further leverage deep generative models for analyzing pooled CRISPR screens to decipher the effects of genetic perturbations on the mechanisms of tumor resistance. This framework resolves distinct modules of immune evasion and survival, including the regulation of the antigen-presentation machinery, interferon/NF-κB signaling, oxidative stress resilience, and checkpoint/cytokine programs, while identifying perturbations that reroute the continuous tumor transcriptional trajectory induced by T cell engagement. A secondary chemical screen in patient-derived GBM cultures identified putative kinase targets of immune evasion phenotypes (e.g., EPHA2 and PDGFRA), whose inhibition leads to the blockade of evasive programs and enhances T cell-mediated GBM killing. Together, this workflow provides a scalable blueprint for comprehensive charting of the genetic control of tumor-immune interactions.

摘要

癌症中的免疫功能障碍是由多种程序引发的,包括肿瘤细胞对不同免疫亚群的内在反应。这些免疫逃逸程序的一部分可以通过直接的肿瘤-免疫相互作用被系统地重现。在这里,我们提出了一个综合的、高通量的单细胞CRISPR筛选框架,该框架聚焦于蛋白激酶组,用于绘制胶质母细胞瘤(GBM)中T细胞驱动的免疫压力的肿瘤内在调控图谱。我们将汇集式CRISPR干扰和激活(CRISPRi/a)与免疫匹配的NY-ESO-1抗原特异性同种异体GBM-T细胞共培养以及大规模多重单细胞转录组学相结合,以系统地量化基因扰动如何在不同效应细胞与靶细胞比例下重塑基线肿瘤状态和适应性反应。我们还利用深度生成模型来分析汇集式CRISPR筛选,以解读基因扰动对肿瘤抗性机制的影响。该框架解析了不同的免疫逃逸和存活模块,包括抗原呈递机制的调控、干扰素/NF-κB信号传导、氧化应激恢复能力以及检查点/细胞因子程序,同时识别出能够改变由T细胞参与诱导的连续肿瘤转录轨迹的扰动。在患者来源的GBM培养物中进行的二次化学筛选确定了免疫逃逸表型的假定激酶靶点(例如,EPHA2和PDGFRA),对其抑制可导致逃逸程序的阻断并增强T细胞介导的GBM杀伤作用。总之,这个工作流程为全面描绘肿瘤-免疫相互作用的基因控制提供了一个可扩展的蓝图。